Enasidenib - Servier
Alternative Names: AG 221 mesylate; AG-221; AGI 12910 mesylate; AGI-12910; CC-90007; IDHIFALatest Information Update: 22 Feb 2024
At a glance
- Originator Agios Pharmaceuticals
- Developer Agios Pharmaceuticals; Celgene Corporation; HOVON Foundation; Massachusetts General Hospital; University Health Network
- Class Amines; Antineoplastics; Fluorinated hydrocarbons; Propanols; Pyridines; Small molecules; Triazines
- Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia
- Phase III Myelodysplastic syndromes
- Phase II Myelofibrosis; Myeloproliferative disorders
- Phase I/II Solid tumours
- No development reported Chronic myelomonocytic leukaemia
Most Recent Events
- 22 Feb 2024 Celgene completes a phase I/II trial in Myelodysplastic syndromes in France and USA (PO) (NCT01915498)
- 22 Dec 2023 Celgene completes a phase II trial in Acute myeloid leukaemia (Second-line therapy or greater) in Australia and South Korea (NCT03720366)
- 09 Dec 2023 Final efficacy and adverse events data from the phase Ib/II ENAVEN-AML trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)